LEOPOLDO VELASCO: Open Payments
NPI 1326112194 · BELL GARDENS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,256 in 74 payments from 8 companies in 2025. Trend: 2023 $504 · 2024 $1,358 · 2025 $2,256
Food & beverage: $2,256
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 19 | $553 |
| Otsuka America Pharmaceutical, Inc. | 19 | $492 |
| E.R. Squibb & Sons, L.L.C. | 13 | $394 |
| Teva Pharmaceuticals USA, Inc. | 4 | $270 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $232 |
| Janssen Pharmaceuticals, Inc | 4 | $229 |
| ABBVIE INC. | 3 | $61 |
| Lundbeck LLC | 1 | $25 |
Products named: ARISTADA, REXULTI, COBENFY, UZEDY, CAPLYTA, INVEGA SUSTENNA, LYBALVI, ABILIFY ASIMTUFII.
Industry payments across CA — which companies pay providers there.
